TBPH — Theravance Biopharma, Inc.

Is TBPH overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Overbought As of August 19, 2026

Theravance Biopharma, Inc. (TBPH) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $16.95. The rating moved from Neutral to Overbought on August 14, 2026.

See all overbought Healthcare stocks →

AI analysis

Theravance Biopharma combines a modest but meaningful near‑term commercial revenue stream with a focused pipeline in respiratory and specialty indications. Existing partner agreements reduce some commercialization execution risk while preserving upside from potential clinical or licensing milestones. Financially the company appears to have a moderate runway but remains sensitive to trial outcomes and any need to access capital, which could dilute equity. Sector dynamics are mixed: short‑term risk‑on flows may support the stock, but longer‑term pressure from payer rationalization and competitive biologics could constrain pricing and uptake. Key near‑term drivers will be partner performance, upcoming clinical newsflow, and any licensing or M&A activity that de‑risks assets. Downside is concentrated around trial or regulatory setbacks and weaker-than-expected commercial adoption; upside would be stronger partner execution and positive clinical readouts that broaden addressable markets.

Key factors

  • Established commercial product revenue stream providing near-term cash (existing respiratory product royalties/licenses and partnered sales)
  • Lean balance sheet relative to larger peers but with sufficient runway given current burn and partnership income (moderate cash runway)
  • Pipeline of specialty respiratory and GI assets with potential upside from clinical readouts or licensing deals
  • Partner relationships that de‑risk commercialization and market access for lead products
  • Macro/market technicals supportive in the near term (risk‑on sentiment and rotation into growth names)
  • Limited direct exposure to the GLP‑1 CDMO supercycle but biotech sector strength can lift small/mid biotech multiples

Risks

  • Clinical trial failure or negative readouts for pipeline assets that could materially impact valuation
  • Pricing and reimbursement pressure from payers and PBMs as sector focus shifts to analytics and margin defense
  • Dependence on partners for commercialization and milestone/royalty flows; partner execution risk
  • Limited product diversification compared with larger biopharma peers, amplifying single‑asset risk
  • Market volatility and sector rotation away from small biotech names on geopolitical or macro headlines
  • Potential dilution from future equity raises if pipeline or commercial performance weakens
  • Regulatory delays or unfavorable labeling that reduce market potential

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for TBPH — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.